Navigation Links
Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
Date:5/3/2012

atients with lupus.  The primary endpoint of PEARL-SC requires patients to demonstrate a greater than or equal to five (>5) point reduction in the SELENA/SLEDAI clinical assessment score, no worsening in physician global assessment, and no new BILAG A or two or more new BILAG B organ domain scores.  Details regarding the study can be found at http://www.clinicaltrials.gov.
  • In conjunction with the PEARL-SC DSMB meeting, an independent statistician conducted an interim efficacy analysis after the 350th enrolled patient reached the 24-week time-point of the study. Following the results of the analysis, the statistician recommended the continuation of the PEARL-SC study to completion. The company is expecting final top-line data this quarter.
  • Manufacturing

  • The Company initiated the development of a pre-filled syringe for the self-administration of subcutaneously delivered blisibimod for phase 3 clinical studies. Stability testing is underway.
  • Management

  • Anthera announced the appointment of Dr. Bogdan Dziurzynski to the board of directors. Dr. Dziurzynski currently serves as a strategic regulatory management consultant to the biotechnology industry and serves on the Board of Directors of Dendreon Corporation and the Biologics Consulting Group, Inc.
  • *SELENA/SLEDAI -- Safety of Estrogen in Lupus Erythematosus National Assessment / Systemic Lupus Erythematosus Activity Index is a cumulative, weighted index of systemic lupus erythematosus disease activity.

    About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

    Safe Harbor Statement

    Any statements contained in this press release that refer to future events or other non-historical matters, including stateme
    '/>"/>

    SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
    (Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
    (Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
    Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
    ... Calif., March 7, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug ... of signal transducer and activator of transcription 3 (STAT3). ... cancers, ISIS-STAT3Rx has the potential to be broadly useful ...
    ... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
    Cached Medicine Technology:Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 2Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 3Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 4Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4
    (Date:7/31/2014)... (PRWEB) July 31, 2014 Cheerag ... experienced, sub-specialty trained neurosurgeons at the Saint Luke’s ... Spine Program and director of spine surgery. He comes ... Wash. , “Dr. Upadhyaya has been recognized for his ... complex spine issues. His addition to the Saint Luke’s ...
    (Date:7/31/2014)... (PRWEB) July 31, 2014 What’s ... practice provider? Community Health Center of Snohomish answers ... Pediatricians vs. Family Doctors ”. Many adults can ... available to them. Community Health Center hopes to ... and differences between the two. , To ...
    (Date:7/31/2014)... Bellava MedAesthetics is proud to introduce ... surgeon! , Dr. Kim has more than a ... the look of their dreams. He focuses on natural ... augmentation (including Gummy Bear implants ), laser liposuction, ... Brazilian butt lift), abdominoplasty (tummy tuck), rhinoplasty, blepharoplasty (eyelid ...
    (Date:7/31/2014)... 2014 When it comes to aesthetics ... and improve. As such, Natalie Sharp's Pure Vitality ... for a new, more focused direction and to provide ... patients! , Pure Vitality Rx is Oyster Bay's premier ... wide variety of services primarily dedicated to women. Services ...
    (Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 Many ... fight for the weak, to correct injustices, and preserve the ... - action that can be lauded as crusading and exemplary ... the lawyer takes on corruption whose seed might be planted ... a fury and the ultimate punishment for an attorney - ...
    Breaking Medicine News(10 mins):Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:Community Health Center of Snohomish County Reveals the Differences Between Pediatricians and Family Practice Providers 2Health News:Bellava MedAesthetics Welcomes Dr. Chang Soo Kim as Its New Westchester Plastic Surgeon 2Health News:Natalie Sharp's Pure Vitality Rx Upgrade - Partnership With Shangri-La Spa and Website Facelift! 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 3
    ... Carolina at Chapel Hill researchers published a study that found ... to have Parkinson,s disease than people with high LDL levels. ... whether low LDL (low-density lipoprotein) levels were present in study ... developed low LDL levels after being diagnosed. , Now a ...
    ... 4, 2008 Smart Balance,Inc. (Nasdaq: SMBL ) ... been named to the position of vice president, business,development. ... vice president,general manager, Midwest. Brett Meltzer has been named ... three are new employees of the,Company., "I am ...
    ... raises prospect of new treatment for tick-borne diseases in ... injection of a long-acting version of the antibiotic doxycycline ... Lyme disease or anaplasmosis, new animal research reveals. , ... raises hope for developing a safer and more effective ...
    ... & Research (NTMir), a,Miami, Florida based not-for-profit organization, ... been awarded to the Research,Institute of the McGill ... Genome Sequence of Mycobacterium avium intracellulare.", The ... NTMir in its innovative,research initiative, Rapid Information Pilot ...
    ... Business and,Disrupt Services to as Many as a Half ... April 4, 2008 A new Medicare,bidding program for ... Cincinnati and Cleveland, Ohio areas on July 1, 2008,will ... likely disrupt,services for many of the 540,000 seniors and ...
    ... A promising vaccine being tested for Alzheimer,s disease does ... plaques from the brain -- but it does not ... according to a University of California, Irvine study. , ... Alzheimer,s disease -- beta-amyloid plaques -- by itself may ...
    Cached Medicine News:Health News:Pieces coming together in Parkinson's, cholesterol puzzle 2Health News:Smart Balance Announces Sales Organization Appointments 2Health News:Smart Balance Announces Sales Organization Appointments 3Health News:Injectable Antibiotic Protects Against Lyme Disease in Mice 2Health News:Injectable Antibiotic Protects Against Lyme Disease in Mice 3Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 2Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 3Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 4Health News:Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment 2
    Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
    ... 2/25 is an economically priced 2-channel ... and research use in the fields ... neurophysiology, biology, zoology, biochemistry and biomedical ... ADInstruments signal conditioners and transducers. Two ...
    ... The PowerLab/4SP is a high-performance data ... of research applications including human and animal ... biomedical engineering. The unit is capable of ... speeds (up to 200 000 samples per ...
    ... Worth 4 Dot with 955R Red/Green ... the presence of binocular vision. Consists ... illuminated discs: two green, one red ... at any distance. Patient wears red/green ...
    Medicine Products: